The DOI matches its Crossref record.
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells
Abstract
In this report, conditions for prolonged in vitro proliferation of polyclonal adult CD4+ T cells via stimulation with immobilized anti-CD3 plus anti-CD28 have been established. CD4+ cells maintained exponential growth for more than 60 days during which a total 10(9)- to 10(11)-fold expansion occurred. Cell cultures exhibited cyclical changes in cell volume, indicating that, in terms of proliferative rate, cells do not have to rest before restimulation. Indeed, electronic cell size analysis was the most reliable method to determine when to restimulate with additional immobilized mAb. The initial approximately 10(5)-fold expansion was autocrine, occurring in the absence of exogenous cytokines or feeder cells. Addition of recombinant human IL-2 after the initial autocrine expansion resulted in continued exponential proliferation. Phorbol ester plus ionomycin also induced long-term growth when combined with anti-CD28 stimulation. Analysis of the T cell repertoire after prolonged expansion revealed a diverse repertoire as assessed by anti-TCR Vbeta Abs or a PCR-based assay. Cytokines produced were consistent with maintenance of both Th1 and Th2 phenotypes; however, the mode of CD3 and CD28 stimulation could influence the cytokine secretion pattern. When anti-CD3 and anti-CD28 were immobilized on the same surface, ELISAs on culture supernatants revealed a pattern consistent with Th1 secretion. Northern analysis revealed that cytokine gene expression remained inducible. Spontaneous growth or cell transformation was not observed in more than 100 experiments. Together, these observations may have implications for gene therapy and adoptive immunotherapy. Furthermore, these culture conditions establish a model to study the finite lifespan of mature T lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citationRapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
Self-citationRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
“While the use of anti-CD3 antibodies alone or in combination with feeder cells and growth factors, such as IL-2, has been the practice for many years, in comparison to beads coated with anti-CD3/anti-CD28 monoclonal antibodies or cell-based artificial APCs (aAPCs), the activation and ex vivo expansion are suboptimal.(…”
BackgroundSelf-citationDecade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Self-citationAntibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Self-citationAdoptive T cell therapy for cancer in the clinic
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32446 · Cited by 553
Self-citationCAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Fu, W., Lei, C., Liu, S., Cui, Y., Wang, C., Qian, K., Li, T., Shen, Y., Fan, X., Lin, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12321-3 · Cited by 496
Pathways of Apoptosis in Lymphocyte Development, Homeostasis, and Disease
Rathmell, J. C., & Thompson, C. B. (2002) · Cell · doi:10.1016/s0092-8674(02)00704-3 · Cited by 495
Self-citationMaus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Self-citationJohnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Self-citationZhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
Self-citationT cells and aging january 2002 update
Pawelec, G. (2002) · Frontiers in Bioscience · doi:10.2741/a831 · Cited by 369
Hippen, K. L., Merkel, S. C., Schirm, D. K., Sieben, C. M., Sumstad, D., Kadidlo, D. M., McKenna, D. H., Bromberg, J. S., Levine, B. L., Riley, J. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001809 · Cited by 365
Self-citationCD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
Chimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 349
Self-citationHoffmann, S. C., Stanley, E. M., Darrin Cox, E., Craighead, N., DiMercurio, B. S., Koziol, D. E., Harlan, D. M., Kirk, A. D., & Blair, P. J. (2001) · Transplantation · doi:10.1097/00007890-200110270-00019 · Cited by 341
Self-citationSubstrate Rigidity Regulates Human T Cell Activation and Proliferation
O’Connor, R. S., Hao, X., Shen, K., Bashour, K., Akimova, T., Hancock, W. W., Kam, L. C., & Milone, M. C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102757 · Cited by 329
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A. A., Schlom, J., June, C. H., & Sherwin, S. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0222-9 · Cited by 325
Self-citationFunctional Study of CD4+CD25+ Regulatory T Cells in Health and Autoimmune Hepatitis
Longhi, M. S., Hussain, M. J., Mitry, R. R., Arora, S. K., Mieli-Vergani, G., Vergani, D., & Ma, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.4484 · Cited by 323
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Self-citationEarly memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Singh, N., Perazzelli, J., Grupp, S. A., & Barrett, D. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5222 · Cited by 303
Rapoport, A. P., Stadtmauer, E. A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., et al. (2005) · Nature Medicine · doi:10.1038/nm1310 · Cited by 290
Self-citationSong, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Self-citationGodfrey, W. R., Ge, Y. G., Spoden, D. J., Levine, B. L., June, C. H., Blazar, B. R., & Porter, S. B. (2004) · Blood · doi:10.1182/blood-2004-01-0151 · Cited by 277
Self-citationSuhoski, M. M., Golovina, T. N., Aqui, N. A., Tai, V. C., Varela-Rohena, A., Milone, M. C., Carroll, R. G., Riley, J. L., & June, C. H. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300134 · Cited by 266
Self-citationAdoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Self-citationPrinciples of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
Self-citationSpaulding, C., Guo, W., & Effros, R. B. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(99)00033-9 · Cited by 258
Das, R. K., Vernau, L., Grupp, S. A., & Barrett, D. M. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1314 · Cited by 255
Liu, K., Schoonmaker, M. M., Levine, B. L., June, C. H., Hodes, R. J., & Weng, N.-P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5147 · Cited by 233
Self-citationCRISPR RNAs Trigger Innate Immune Responses in Human Cells
Kim, S., Koo, T., Jee, H.-G., Cho, H.-Y., Lee, G., Lim, D.-G., Shin, H. S., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.231936.117 · Cited by 222
Maier, D. A., Brennan, A. L., Jiang, S., Binder-Scholl, G. K., Lee, G., Plesa, G., Zheng, Z., Cotte, J., Carpenito, C., Wood, T., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.172 · Cited by 126
“…expansion rate mediated by PHA, PMA, and anti-CD3/ CD28 stimulation is roughly equivalent during the first 5–7 days poststimulation, only costimulation via anti-CD3/ CD28 enables extensive expansion of functional T cells secreting high levels of cytokines and chemokines (Levine et al., 1997).”
BackgroundMethodInfluentialSelf-citationEffros, R. B. (1998) · The American Journal of Human Genetics · doi:10.1086/301845 · Cited by 105
“…derived from peripheral blood of healthy young adult donors are propagated in cell culture by repeated stimulation with antigen (Abidzadeh et al. 1996 ) or with appropriate activating antibodies (Levine et al. 1997) and continuous exposure to the T cell–specific growth factor, interleukin-2 (IL-2).”
BackgroundGrabert, R. C., Cousens, L. P., Smith, J. A., Olson, S., Gall, J., Young, W. B., Davol, P. A., & Lum, L. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2005 · Cited by 79
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
Charan, M., Dravid, P., Cam, M., Audino, A., Gross, A. C., Arnold, M. A., Roberts, R. D., Cripe, T. P., Pertsemlidis, A., Houghton, P. J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32743 · Cited by 59
“The timing of restimulation was based on prior studies.(30,40) As shown in Figure 5g, repeated stimulation with GD2-expressing cells allowed CAR-T cells to continue to expand, whereas lack of antigen stimulation on UTDs resulted in culture growth arrest.”
MethodEngineering of synthetic cellular microenvironments: Implications for immunity
Adutler-Lieber, S., Zaretsky, I., Platzman, I., Deeg, J., Friedman, N., Spatz, J. P., & Geiger, B. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.05.003 · Cited by 39
MacDonald, K. N., Ivison, S., Hippen, K. L., Hoeppli, R. E., Hall, M., Zheng, G., Dijke, I. E., Aklabi, M. A., Freed, D. H., Rebeyka, I., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.10.011 · Cited by 30
Metadata
- Authors
- Levine, B. L., Bernstein, W. B., Connors, M., Craighead, N., Lindsten, T., Thompson, C. B., & June, C. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-12
- Volume
- 159
- Issue
- 12
- Pages
- 5921-5930
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2121230396
- Cited by
- 340
- References
- 0
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.